Literature DB >> 23380568

Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects.

Chan Joo Lee1, Yong-Ho Lee, Sahng Wook Park, Kwang Joon Kim, Sungha Park, Jong-Chan Youn, Sang-Hak Lee, Seok-Min Kang, Yangsoo Jang.   

Abstract

OBJECTIVE: The clinical significance of the measurement of serum PCSK9 (proprotein subtilisin kexin type 9) is not well defined. This study investigated the association between serum PCSK9 levels and atherosclerosis assessed by carotid intima media thickness (IMT) in hypertensive patients.
METHODS: A total of 126 hypertensive patients over the age of 45 were enrolled. The maximum carotid IMT (max-IMT) and the mean carotid IMT (mean-IMT) were measured at the time of enrollment. Clinical and laboratory parameters including serum PCSK9 were analyzed.
RESULTS: Patients were divided into tertiles based on serum PCSK9 levels. After adjusting for age, sex, total cholesterol, HDL-cholesterol and triglyceride, max-IMT was significantly increased in the highest tertile of serum PCSK9 (0.969±0.033 vs 0.959±0.033 vs 1.077±0.033 mm, respectively; P=0.026). Mean-IMT showed a tendency to increase across the tertile groups (0.773±0.025 vs 0.790±0.026 vs 0.856±0.025 mm, respectively; P=0.059). Multivariate regression analysis revealed that serum PCSK9 was independently associated with carotid IMT (max-IMT: β=0.212, P=0.016; mean-IMT: β=0.184, P=0.04).
CONCLUSION: The present study is the first to report the association between serum PCSK9 levels and carotid IMT in hypertensive patients. These results suggest that serum PCSK9 may have a certain role in early pathogenesis of atherosclerosis.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23380568     DOI: 10.1016/j.metabol.2013.01.005

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  13 in total

Review 1.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

2.  Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima-media thickness in hypertensives.

Authors:  Sheng-Hua Yang; Ying Du; Sha Li; Yan Zhang; Rui-Xia Xu; Cheng-Gang Zhu; Yuan-Lin Guo; Na-Qiong Wu; Qian Dong; Jing Sun; Jian-Jun Li
Journal:  Hypertens Res       Date:  2016-04-14       Impact factor: 3.872

Review 3.  Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).

Authors:  Rainer Schulz; Klaus-Dieter Schlüter; Ulrich Laufs
Journal:  Basic Res Cardiol       Date:  2015-01-20       Impact factor: 17.165

4.  Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.

Authors:  Elzbieta Sucajtys-Szulc; Marek Szolkiewicz; Julian Swierczynski; Boleslaw Rutkowski
Journal:  Mol Cell Biochem       Date:  2015-10-19       Impact factor: 3.396

5.  Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.

Authors:  Massimiliano Ruscica; Nicola Ferri; Federica Fogacci; Martina Rosticci; Margherita Botta; Silvia Marchiano; Paolo Magni; Sergio D'Addato; Marina Giovannini; Claudio Borghi; Arrigo F G Cicero
Journal:  J Am Heart Assoc       Date:  2017-05-03       Impact factor: 5.501

Review 6.  PCSK9 and Atherosclerosis - Lipids and Beyond.

Authors:  Michael D Shapiro; Sergio Fazio
Journal:  J Atheroscler Thromb       Date:  2017-03-09       Impact factor: 4.928

Review 7.  Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.

Authors:  Eunhye Ji; Sahmin Lee
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 8.  Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.

Authors:  Marianne Abifadel; Sandy Elbitar; Petra El Khoury; Youmna Ghaleb; Mélody Chémaly; Marie-Line Moussalli; Jean-Pierre Rabès; Mathilde Varret; Catherine Boileau
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.967

9.  Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.

Authors:  Ting-Hsing Chao; I-Chih Chen; Yi-Heng Li; Po-Tseng Lee; Shih-Ya Tseng
Journal:  J Am Heart Assoc       Date:  2016-05-20       Impact factor: 5.501

10.  Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.

Authors:  Jian-Jun Li; Sha Li; Yan Zhang; Rui-Xia Xu; Yuan-Lin Guo; Cheng-Gang Zhu; Na-Qiong Wu; Ping Qing; Ying Gao; Jing Sun; Geng Liu; Qian Dong
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.